And Citrus Fruits
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity
toxins Article Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity Massimo Picardo 1 , Oscar Núñez 2,3 and Marinella Farré 1,* 1 Department of Environmental Chemistry, IDAEA-CSIC, 08034 Barcelona, Spain; [email protected] 2 Department of Chemical Engineering and Analytical Chemistry, University of Barcelona, 08034 Barcelona, Spain; [email protected] 3 Serra Húnter Professor, Generalitat de Catalunya, 08034 Barcelona, Spain * Correspondence: [email protected] Received: 5 October 2020; Accepted: 26 November 2020; Published: 28 November 2020 Abstract: This study presents the application of a suspect screening approach to screen a wide range of natural toxins, including mycotoxins, bacterial toxins, and plant toxins, in surface waters. The method is based on a generic solid-phase extraction procedure, using three sorbent phases in two cartridges that are connected in series, hence covering a wide range of polarities, followed by liquid chromatography coupled to high-resolution mass spectrometry. The acquisition was performed in the full-scan and data-dependent modes while working under positive and negative ionisation conditions. This method was applied in order to assess the natural toxins in the Ter River water reservoirs, which are used to produce drinking water for Barcelona city (Spain). The study was carried out during a period of seven months, covering the expected prior, during, and post-peak blooming periods of the natural toxins. Fifty-three (53) compounds were tentatively identified, and nine of these were confirmed and quantified. Phytotoxins were identified as the most frequent group of natural toxins in the water, particularly the alkaloids group. -
The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism. -
Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate. -
Bergamot Oil: Botany, Production, Pharmacology
Entry Bergamot Oil: Botany, Production, Pharmacology Marco Valussi 1,* , Davide Donelli 2 , Fabio Firenzuoli 3 and Michele Antonelli 2 1 Herbal and Traditional Medicine Practitioners Association (EHTPA), Norwich NR3 1HG, UK 2 AUSL-IRCCS Reggio Emilia, 42122 Reggio Emilia RE, Italy; [email protected] (D.D.); [email protected] (M.A.) 3 CERFIT, Careggi University Hospital, 50139 Firenze FI, Italy; fabio.firenzuoli@unifi.it * Correspondence: [email protected] Definition: Bergamot essential oil (BEO) is the result of the mechanical manipulation (cold pressing) of the exocarp (flavedo) of the hesperidium of Citrus limon (L.) Osbeck Bergamot Group (synonym Citrus × bergamia Risso & Poit.), resulting in the bursting of the oil cavities embedded in the flavedo and the release of their contents. It is chemically dominated by monoterpene hydrocarbons (i.e., limonene), but with significant percentages of oxygenated monoterpenes (i.e., linalyl acetate) and of non-volatile oxygen heterocyclic compounds (i.e., bergapten). Keywords: bergamot; citrus; essential oil; production; review 1. Introduction The taxonomy, and consequently the nomenclature, of the genus Citrus, is particularly complicated and has been rapidly changing in recent years (see Table1). For over 400 years, the centre of origin and biodiversity, along with the evolution and phylogeny of the Citrus species, have all been puzzling problems for botanists and the confusing and changing Citation: Valussi, M.; Donelli, D.; nomenclature of this taxon over the years can reflect intrinsic reproductive features of Firenzuoli, F.; Antonelli, M. Bergamot Oil: Botany, Production, the species included in this genus, the cultural and geographical issues, and the rapidly Pharmacology. Encyclopedia 2021, 1, evolving techniques used to clarify its phylogeny [1]. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
The Title Is in Blue Arial 32 Bold
Recent Developments to Detect Lemon Juice Adulteration Authors: Ramin Jahromi, Hayley Pratt, Yang Zhou, Lars Reimann: Eurofins Nutrition Analysis Center, 2200 Rittenhouse St, Suite 175, Des Moines, IA 50321, USA ([email protected]) Dr. David A Hammond : Eurofins Scientific Analytics, Rue Pierre Adolphe Bobierre, F-44323, Nantes, France. Citropten Abstract: One of the possible adulterants of lemon juice is lime. The pattern of PMFs seen in lemon and lime juices are very different, which allow a much easier identification of substitution and/or addition of lime to lemon. This poster describes the method for the polymethoxyflavones “lime” markers. Introduction Discussion: Figure 2: PMF profile for lemon juice Unfortunately there is a long history of economic adulteration of fruit juices. The first well Experts from the European juice association (AIJN) have drawn up the typical ranges for a number publicized case of juice fraud was in 1989 with Beech-nut(1). This and subsequent events (10) of important juice components in 25 fruits and vegetables , which are extremely useful in the Citropten have meant that juice packers normally have a “verification” program for their raw assessment of the quality and authenticity of these products. They also working on a reference materials to ensure that they are authentic. Although in 2009 the FDA officially recognized guide for lime at present. food fraud as an emerging risk to the consumer, in fringe industries that use juice based Lemon and lime juices are normally adulterated by substitution of some or all of the juice solids by products, this risk had not been recognized and few companies have QA programs in place. -
Phototherapy* Fototerapia*
RevABDV81N1.qxd 17.02.06 15:55 Page 74 74 Artigo de Revisão Fototerapia* Phototherapy* Ida Duarte 1 Roberta Buense 2 Clarice Kobata 3 Resumo: Fototerapia é utilizada para tratar uma grande variedade de dermatoses. Desde o século pas- sado a fototerapia tem sido utilizada em várias modalidades, com irradiação UVA ou UVB. Está indica- da para todos os tipo de dermatoses inflamatórias e com período crônico de evolução, como vitiligo, pasoríase, parapsoríase, linfomas cutâneos de células T, eczemas crônicos, demonstrando bons resulta- dos terapêuticos. Pode ser utilizada como monoterapia ou associada a outras drogas, como retinóides, metotrexate, ciclos- porina, com objetivo de diminuir o tempo de tratamento e as doses das medicações mencionadas. Como os demais tipos de tratamento, a fototerapia apresenta algumas limitações, como a necessidade de equipamentos específicos, a adesão do paciente, a possibilidade de indicação ao paciente e a dose cumulativa de irradiação UV. A fototerapia deve ser conduzida com seguimento criterioso para a obtenção de resposta efetiva com poucos efeitos colaterais. Palavras-chave: Fototerapia; Inflamação; Raios ultravioleta; Terapia PUVA Abstract: Phototherapy has been used to treat a large variety of dermatoses since the past century. It is classified according to the type of irradiation (UVA or UVB). Phototherapy is indicated for all types of inflammatory and chronic skin diseases, such as vitiligo, psoriasis, parapsoriasis, cutaneous T-cell lymphomas and chronic eczemas, with good therapeutic results. It can be used as monotherapy or associated with others drugs, such as retinoids, methotrexate and cyclosporine, aiming to reduce length of treatment and doses. Like other treatments, phototherapy has some limitations - it requires specific equipment, patient's compliance, has restricted indications and leads to cumulative UV doses. -
Alphabetical Listing of ATC Drugs & Codes
Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04 -
Psoralen Photochemistry and Nucleic Acid Structure
0022-202X/ 8 1/ 770 1-00J9$02.00/ 0 THE JOURNAL OF I NV r, STIGATIVE DEIlMATOLOGY, 77:39-44, IH8 1 Vol. 77, No. I Copy righ t © 198 1 by The Williams & Wilkins Co. Printed ill U.S.A. Psoralen Photochemistry and Nucleic Acid Structure JOHN E. H EARST, PH.D. Departm.ent of Chemistry, University of California, B erkeley, California, U.S.A . Many new psorale n derivatives have b een synthesized nated in the production of many new psoralens, several of which in an effort to enhance their water solubility and their have superior photoreactivity with both DNA and RNA as binding to nucleic acids. Availability of the very soluble compared to TMP and 8-MOP. The 5 new derivatives shown strongly binding compounds has improved our abilities here are 4' adducts of TMP and their structW"es ru-e shown (3 - to follow the optical changes associated with the photo 7). T he complete characterization of methoxymethyltrioxsalen chemistry of psoralens with DNA. Changes in both ab (MMT, 4) , hydroxymethyltrioxsalen (HMT, 5) and aminome sorbance and fluoresce nce are prese nted in this r eview. thyltrioxsalen (AMT, 7) wi th respect to their reactivity with A kinetic model for the photochemistry concludes that nucleic acids, including a theoretical treatment, is described in the detailed kinetics is dominated by the equilibrium a recent paper by Isaacs et al [6]. A related set of soluble 8- constant for intercalation of the psoralen in the DNA, methoxypsoralen derivatives have been synthesized by Isaacs, the quantum yield for photoaddition to DNA once inter Chun, a nd Hearst [7] a nd ru'e listed as compounds 8-11. -
(12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct. -
Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: Active Moiety Name “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13. -
Bergapten Improves Scopolamine-Induced Memory Impairment in Mice Via Cholinergic and Antioxidative Mechanisms
fnins-14-00730 August 4, 2020 Time: 15:39 # 1 ORIGINAL RESEARCH published: 06 August 2020 doi: 10.3389/fnins.2020.00730 Bergapten Improves Scopolamine-Induced Memory Impairment in Mice via Cholinergic and Antioxidative Mechanisms Joanna Kowalczyk1,2, Łukasz Kurach2, Anna Boguszewska-Czubara3, Krystyna Skalicka-Wo´zniak4, Marta Kruk-Słomka5, Jacek Kurzepa3, Małgorzata Wydrzynska-Ku´zma5, Grazyna˙ Biała5, Adrianna Skiba4 and Barbara Budzynska´ 2* 1 Chair and Department of Applied Pharmacy, Medical University of Lublin, Lublin, Poland, 2 Independent Laboratory of Behavioral Studies, Medical University of Lublin, Lublin, Poland, 3 Chair and Department of Medicinal Chemistry, Medical University of Lublin, Lublin, Poland, 4 Chair and Department of Pharmacognosy with Medicinal Plant Unit, Medical University Edited by: of Lublin, Lublin, Poland, 5 Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Maria Javier Ramirez, Lublin, Poland University of Navarra, Spain Reviewed by: Patrizio Blandina, Bergapten is a furanocoumarin naturally occurring in the Apiaceae family and it is a well- University of Florence, Italy known photosensitizing agent used in photochemotherapy. In this study, we investigated Mariela Fernanda Perez, the influence of bergapten on cognitive function and mechanism underlying these effects National University of Córdoba, Argentina in scopolamine-induced memory impairment in male Swiss mice. The passive avoidance *Correspondence: test was used to evaluate the efficiency of memory acquisition and consolidation. Barbara Budzynska´ The results demonstrated that both single and repeated administration of bergapten [email protected] improved not only the acquisition but also consolidation of memory. The behavioral Specialty section: tests showed that bergapten prevented memory impairment induced by administration This article was submitted to of scopolamine.